Search

Your search keyword '"Tabet, Fatiha"' showing total 165 results
Start Over Author "Tabet, Fatiha"
165 results on '"Tabet, Fatiha"'

1. Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors

Author

Ong, Kwok Leung, McClelland, Robyn L, Allison, Matthew A, Cushman, Mary, Garg, Parveen K, Tsai, Michael Y, Rye, Kerry-Anne, and Tabet, Fatiha

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Heart Disease, Atherosclerosis, Cardiovascular, Clinical Research, Heart Disease - Coronary Heart Disease, Good Health and Well Being, Aged, Aged, 80 and over, Biomarkers, Case-Control Studies, Coronary Artery Disease, Coronary Vessels, Female, Humans, Lipoprotein(a), Male, Middle Aged, Prospective Studies, Risk Factors, United States, Vascular Calcification, Blood coagulation, Coronary artery calcification, Inflammation, Lipoprotein, Multi-Ethnic Study of Atherosclerosis, Endocrinology & Metabolism, Clinical sciences
Abstract

BackgroundElevated plasma lipoprotein (a) [Lp(a)] and coronary artery calcification (CAC) are established cardiovascular risk factors that correlate with each other. We hypothesized that other cardiovascular risk factors could affect their relationship.MethodsWe tested for interactions of 24 study variables related to dyslipidemia, diabetes, insulin resistance, hypertension, inflammation and coagulation with baseline Lp(a) on change in CAC volume and density over 9.5 years in 5975 Multi-Ethnic Study of Atherosclerosis (MESA) participants, free of apparent cardiovascular disease at baseline.ResultsElevated Lp(a) was associated with larger absolute increase in CAC volume (3.21 and 4.45 mm3/year higher for Lp(a) ≥30 versus

Published
2021

2. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk

Author

Arsenault, Benoit J, Petrides, Francine, Tabet, Fatiha, Bao, Weihang, Hovingh, G Kees, Boekholdt, S Matthijs, Ramin-Mangata, Stéphane, Meilhac, Olivier, DeMicco, David, Rye, Kerry-Anne, Waters, David D, Kastelein, John JP, Barter, Philip, and Lambert, Gilles

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Clinical Sciences, Heart Disease, Diabetes, Clinical Trials and Supportive Activities, Atherosclerosis, Cardiovascular, Clinical Research, Heart Disease - Coronary Heart Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Metabolic and endocrine, Good Health and Well Being, Aged, Atorvastatin, Cardiovascular Diseases, Cholesterol Ester Transfer Proteins, Cholesterol, LDL, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Humans, Lipoprotein(a), Male, Middle Aged, Placebo Effect, Proprotein Convertase 9, Quinolines, Risk Factors, Treatment Outcome, Diabetes mellitus, PCSK9, CETP, Medical Biochemistry and Metabolomics, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Medical biochemistry and metabolomics
Abstract

BackgroundProprotein subtilisin kexin type 9 (PCSK9) and lipoprotein (a) [Lp(a)] levels are causative risk factors for coronary heart disease.ObjectivesThe objective of the study was to determine the impact of lipid-lowering treatments on circulating PCSK9 and Lp(a).MethodsWe measured PCSK9 and Lp(a) levels in plasma samples from Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial patients with coronary heart disease and/or type II diabetes (T2D) mellitus. Patients received atorvastatin, which was titrated (10, 20, 40, or 80 mg/d) to achieve low-density lipoprotein cholesterol levels

Published
2018

10. MicroRNA-223 coordinates cholesterol homeostasis

Author

Vickers, Kasey C., Landstreet, Stuart R., Levin, Michael G., Shoucri, Bassem M., Toth, Cynthia L., Taylor, Robert C., Palmisano, Brian T., Tabet, Fatiha, Cui, Huanhuan L., Rye, Kerry-Anne, Sethupathy, Praveen, and Remaley, Alan T.

Published
2014

13. High density lipoprotein-associated miRNA is increased following Roux-en-Y gastric bypass surgery for severe obesity

Author

Ho, Jan Hoong, primary, Ong, Kwok Leung, additional, Cuesta Torres, Luisa F., additional, Liu, Yifen, additional, Adam, Safwaan, additional, Iqbal, Zohaib, additional, Dhage, Shaishav, additional, Ammori, Basil J., additional, Syed, Akheel A., additional, Rye, Kerry-Anne, additional, Tabet, Fatiha, additional, and Soran, Handrean, additional

Published
2021
Full Text
View/download PDF

14. CONTRIBUTORS

Author

Ahooja, Vineeta, primary, Ajay, Vamadevan S., additional, Amar, Laurence, additional, Appel, Lawrence J., additional, Azizi, Michel, additional, Bakris, George L., additional, Bazzano, Lydia A., additional, Beevers, D. Gareth, additional, Beilin, Lawrence J., additional, Blann, Andrew D., additional, Boegehold, Matthew A., additional, Booz, George W., additional, Braam, Branko, additional, Brandon, Elizabeth L., additional, Brands, Michael W., additional, Britton, Mark, additional, Brunner, Hans R., additional, Burke, Beverley, additional, Burke, Valerie, additional, Cappuccio, Francesco P., additional, Carey, Robert M., additional, Carter, Barry L., additional, Caulfield, Mark J., additional, Chen, Yuqing, additional, Cohn, Jay N., additional, Connell, John M.C., additional, Cox, Anthony, additional, Das, Madhusudan, additional, Davy, Kevin P., additional, Dennison, Cheryl R., additional, Sarkissian, Shant Der, additional, Díez, Javier, additional, Doris, Peter A., additional, Drummond, Heather A., additional, Duprez, Daniel A., additional, Elijovich, Fernando, additional, Elliott, Henry L., additional, Elliott, William J., additional, Eveson, David J., additional, Fink, Gregory D., additional, Fiotti, Nicola, additional, Flack, John M., additional, Flynn, Joseph T., additional, Foëx, Pierre, additional, Fortepiani, Lourdes A., additional, Fotherby, Martin D., additional, Fouad-Tarazi, Fetnat, additional, Franklin, Stanley S., additional, Friese, Ryan, additional, Funder, John W., additional, Galligan, James J., additional, Garvin, Jeffrey L., additional, Gentile, Christopher L., additional, George, Jacob, additional, Ghiadoni, Lorenzo, additional, Giansante, Carlo, additional, Gilbert, Richard E., additional, Gomez, Sabas I., additional, Gradman, Alan H., additional, Granger, Joey P., additional, Grassi, Guido, additional, Greenland, Philip, additional, Grossman, Ehud, additional, Gungadoo, Johannie, additional, Haas, John A., additional, Hahn, Peter Y., additional, Hall, John E., additional, Hamilton, Bruce A., additional, Haywood, Joseph R., additional, He, Jiang, additional, Herrera, Marcela, additional, Hill, Martha N., additional, Iliescu, Radu, additional, Isles, Chris, additional, Izzo, Joseph L., additional, Jaumdally, Rumi, additional, Jones, Daniel W., additional, Kearney, Patricia M., additional, Koomans, Hein A., additional, Krasuski, Richard A., additional, Krum, Henry, additional, Laffer, Cheryl L., additional, Lang, Chim C., additional, Langford, Nigel J., additional, Lawlor, Debbie A., additional, Lee, Dexter L., additional, Lévy, Bernard I., additional, Link, Daniel, additional, Lip, Gregory Y.H., additional, Lipkin, Graham W., additional, Lloyd-Jones, Donald M., additional, Lohmeier, Thomas E., additional, Loughrey, Brona V., additional, MacDonald, Thomas M., additional, MacFadyen, Robert J., additional, Mahata, Sushil K., additional, Mancia, Giuseppe, additional, Marçano, Ana Carolina B., additional, Martin, Jennifer, additional, McGiff, John C., additional, McInnes, Gordon T., additional, Messerli, Franz H., additional, Miller, Steven M., additional, Mitchell, Paul, additional, Moore, Jason, additional, Mori, Trevor A., additional, Moser, Marvin, additional, Mugo, Maryann N., additional, Munroe, Patricia B., additional, Naik, Nitish, additional, Nasser, Samar A., additional, Newhouse, Stephen J., additional, Ng, Leong L., additional, Northcott, Carrie A., additional, O'Connor, Shannon M., additional, O'Connor, Daniel T., additional, Oparil, Suzanne, additional, Ortiz, Pablo A., additional, Panjrath, Gurusher S., additional, Parthasarathy, Hari Krishnan, additional, Perry, Ivan J., additional, Pickering, Thomas G., additional, Plouin, Pierre-François, additional, Prabhakaran, Dorairaj, additional, Puddey, Ian B., additional, Quilley, John, additional, Raizada, Mohan K., additional, Rao, Fangwen, additional, Reckelhoff, Jane F., additional, Reddy, Kolli Srinath, additional, Rizzoni, Damiano, additional, Robertson, J. Ian S., additional, Robinson, Thompson G., additional, Romero, J. Carlos, additional, Rosei, Enrico Agabiti, additional, Rosenthal, Talma, additional, Rosskopf, Dieter, additional, Ryan, Michael J., additional, Safar, Michel E., additional, Salvetti, Antonio, additional, Sarafidis, Panteleimon A., additional, Sartori-Valinotti, Julio C., additional, Schork, Nicholas J., additional, Setaro, John F., additional, Shah, N.C., additional, Shiel, Julian, additional, Schiffrin, Ernesto L., additional, Sica, Domenic A., additional, Silva, Alexandre A. da, additional, Silva, Guillermo B., additional, Silva, J. Enrique, additional, Smith, George Davey, additional, Somers, Virend K., additional, Sowers, James R., additional, Spence, J. David, additional, Stanley, Adrian G., additional, Stec, David E., additional, Stranges, Saverio, additional, Struthers, Allan D., additional, Stump, Craig S., additional, Tabet, Fatiha, additional, Taddei, Stefano, additional, Taupenot, Laurent, additional, Tayebjee, Muzahir H., additional, Teixeira, Cleber E., additional, Thakali, Keshari M., additional, Touyz, Rhian M., additional, Traub, Darren, additional, Tse, Hung-Fat, additional, Umans, Jason G., additional, Uthappa, Puchimada, additional, Valina-Toth, Anna B., additional, Varughese, George I., additional, Virdis, Agostino, additional, Watts, Stephanie W., additional, Webb, R. Clinton, additional, Wen, Gen, additional, Whelton, Paul K., additional, Whitworth, Judith A., additional, Wong, Tien Yin, additional, Woodham, Ryan M., additional, Wyne, Kathleen, additional, Yanes, Licy Lorena, additional, Ying, Zhekang, additional, Young, Ian S., additional, Zanchetti, Alberto, additional, Zhang, Kuixing, additional, Zhang, Lian, additional, and Ziegler, Michael G., additional

Published
2007
Full Text
View/download PDF

18. microRNA-367-3p regulation of GPRC5A is suppressed in ischemic stroke

Author

Tabet, Fatiha, primary, Lee, Seyoung, additional, Zhu, Wanying, additional, Levin, Michael G, additional, Toth, Cynthia L, additional, Cuesta Torres, Luisa F, additional, Vinh, Antony, additional, Kim, Hyun Ah, additional, Chu, Hannah X, additional, Evans, Megan A, additional, Kuzmich, Meaghan E, additional, Drummond, Grant R, additional, Remaley, Alan T, additional, Rye, Kerry-Anne, additional, Sobey, Christopher G, additional, and Vickers, Kasey C, additional

Published
2019
Full Text
View/download PDF

20. The Effects of Cholesteryl Ester Transfer Protein Inhibition on High Density Lipoprotein Function

Author

Rye, Kerry-Anne, Medical Sciences, Faculty of Medicine, UNSW, Thomas, Shane, Medical Sciences, Faculty of Medicine, UNSW, Tabet, Fatiha, Medical Sciences, Faculty of Medicine, UNSW, Shrestha, Sudichhya, Medical Sciences, Faculty of Medicine, UNSW, Rye, Kerry-Anne, Medical Sciences, Faculty of Medicine, UNSW, Thomas, Shane, Medical Sciences, Faculty of Medicine, UNSW, Tabet, Fatiha, Medical Sciences, Faculty of Medicine, UNSW, and Shrestha, Sudichhya, Medical Sciences, Faculty of Medicine, UNSW

Abstract

Cardiovascular disease affects about 1.4 million Australians and was responsible for more than 45000 deaths in 2011. Compelling evidence from human population studies has shown a positive correlation between elevated plasma high density lipoprotein cholesterol (HDL-C) levels and a reduced risk of major cardiovascular events. HDLs have several potential cardioprotective functions, the most extensively studied of which is their ability to remove excess cholesterol from macrophages. They also have anti-inflammatory properties, enhance endothelial repair and improve endothelial function. HDLs also have anti-oxidant, anti-apoptotic, anti-thrombotic and anti-diabetic functions. Therapies that increase HDL-C levels reduce atherosclerotic lesion development in animals. These observations have led to the hypothesis that increasing HDL-C levels will reduce cardiovascular events in humans. Although CETP inhibitors have been shown to markedly increase HDL-C levels and reduce major cardiovascular events in a recent clinical outcome trial, there remains doubt about the effects of CETP inhibition on the cardioprotective properties of HDLs. The work in this thesis examines the effects of inhibiting CETP on the cardioprotective functions of HDLs. The studies investigate the effects of a novel CETP inhibitor, AMG-899, on HDL composition, size and several of their cardioprotective properties. Subjects were treated with placebo or AMG-899 (2.5 mg/day or 10 mg/day) over 12 weeks. HDLs were isolated from subjects before and after treatment. AMG-899 treatment increased plasma HDL-C levels and decreased LDL-C levels (Chapter 3). Treatment with AMG-899 also changed the composition of HDLs, increased HDL size (Chapter 3) and increased HDL-mediated ABCA1- and ABCG1-specific cholesterol efflux (Chapter 4). Treatment with 10 mg/day AMG-899 also improved the anti-inflammatory properties of HDLs (Chapter 5), while HDLs isolated from subjects after treatment with 2.5 mg/day and 10 mg/day AMG-899 w

Published
2018

21. Erratum. Impact of Perturbed Pancreatic β-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism. Diabetes 2016;65:3610–3620

Author

Cochran, Blake J., primary, Hou, Liming, additional, Manavalan, Anil Paul Chirackal, additional, Moore, Benjamin M., additional, Tabet, Fatiha, additional, Sultana, Afroza, additional, Cuesta Torres, Luisa, additional, Tang, Shudi, additional, Shrestha, Sudichhya, additional, Senanayake, Praween, additional, Patel, Mili, additional, Ryder, William J., additional, Bongers, Andre, additional, Maraninchi, Marie, additional, Wasinger, Valerie C., additional, Westerterp, Marit, additional, Tall, Alan R., additional, Barter, Philip J., additional, and Rye, Kerry-Anne, additional

Published
2016
Full Text
View/download PDF

23. Impact of Perturbed Pancreatic β-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism

Author

Cochran, Blake J., primary, Hou, Liming, additional, Manavalan, Anil Paul Chirackal, additional, Moore, Benjamin M., additional, Tabet, Fatiha, additional, Sultana, Afroza, additional, Cuesta Torres, Luisa, additional, Tang, Shudi, additional, Shrestha, Sudichhya, additional, Senanayake, Praween, additional, Patel, Mili, additional, Ryder, William J., additional, Bongers, Andre, additional, Maraninchi, Marie, additional, Wasinger, Valerie C., additional, Westerterp, Marit, additional, Tall, Alan R., additional, Barter, Philip J., additional, and Rye, Kerry-Anne, additional

Published
2016
Full Text
View/download PDF

30. Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial (Retracted article. See vol. 61, pg. 1751, 2013)

Author

Huijgen, Roeland, Boekholdt, S. Matthijs, Arsenault, Benoit J., Bao, Weihang, Davaine, Jean-Michel, Tabet, Fatiha, Petrides, Francine, Rye, Kerry-Anne, Demicco, David A., Barter, Philip J., Kastelein, John J. P., Lambert, Gilles, Other departments, Amsterdam Cardiovascular Sciences, Cardiology, and Vascular Medicine

Subjects
lipids (amino acids, peptides, and proteins)
Abstract

Objectives The purpose of this study was to investigate whether high levels of circulating proprotein convertase subtilisin kexin type 9 (PCSK9) would increase cardiovascular risk in statin-treated patients. Background Statins activate low-density lipoprotein (LDL) receptor gene expression, thus lowering plasma LDL levels. But statins also activate the expression of PCSK9, a secreted inhibitor of the LDL receptor, thereby limiting their beneficial effects. Methods We have measured the plasma PCSK9 levels of 1,613 patients with stable coronary heart disease enrolled in the Treating to New Targets study, a randomized trial that compared the efficacy of high-versus low-dose atorvastatin. After a run-in period with atorvastatin 10 mg daily, patients were randomized to either continue with 10 mg or be up-titrated to 80 mg of atorvastatin, and followed during 5 years for major cardiovascular events (MCVEs). Results Circulating PCSK9 levels measured at randomization were predictive of clinical outcomes in the group randomized to remain on atorvastatin 10 mg (p = 0.039), but not in the group that intensified atorvastatin treatment to 80 mg (p = 0.24). Further, PCSK9 levels measured 1 year post-randomization did not change upon increase of the statin dose. Conclusions PCSK9 levels predict cardiovascular events in patients treated with low-dose atorvastatin. (A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels [TNT]; NCT00327691) (J Am Coll Cardiol 2012;59:1778-84) (C) 2012 by the American College of Cardiology Foundation

Published
2012

33. La signalisation redox en hypertension artérielle

Author

Tabet, Fatiha, Touyz, Rhian Merry, and Schiffrin, Ernesto Luis

Subjects
Signalisation calcique, Angiotensine II, Hypertension essentielle, Croissance des CMLVs, Dérivés réactifs de l'oxygène, Oxydation des PTPs
Abstract

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

Published
2007

34. Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects

Author

Lambert, Gilles, primary, Petrides, Francine, additional, Chatelais, Mathias, additional, Blom, Dirk J., additional, Choque, Benjamin, additional, Tabet, Fatiha, additional, Wong, Gida, additional, Rye, Kerry-Anne, additional, Hooper, Amanda J., additional, Burnett, John R., additional, Barter, Philip J., additional, and Marais, A. David, additional

Published
2014
Full Text
View/download PDF

36. Abstract 3: HDL-MicroRNA-92a and Interleukin-33 Axis Underlies Endothelial Dysfunction Associated With Atherosclerosis and Chronic Kidney Disease

Author

Wiese, Carrie B, primary, Toth, Cynthia L, additional, Tabet, Fatiha, additional, Taylor, Robert C, additional, Landstreet, Stuart R, additional, Rye, Kerry-Anne, additional, Hofmeister, Lucas H, additional, Harrison, David G, additional, Kon, Valentina, additional, and Vickers, Kasey C, additional

Published
2014
Full Text
View/download PDF

38. Abstract 612: Effect of Bariatric Surgery on HDL-Associated MicroRNAs

Author

Tabet, Fatiha, primary, Vickers, Kasey C, additional, Cuesta Torres, Luisa F, additional, Ammori, Basil, additional, Yadav, Rahul, additional, Hama, Salam, additional, Liu, Yifen, additional, Schofield, Jonathan, additional, Barter, Philip, additional, Soran, Handrean, additional, and Rye, Kerry-Anne, additional

Published
2014
Full Text
View/download PDF

40. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells

Author

Tabet, Fatiha, primary, Vickers, Kasey C., additional, Cuesta Torres, Luisa F., additional, Wiese, Carrie B., additional, Shoucri, Bassem M., additional, Lambert, Gilles, additional, Catherinet, Claire, additional, Prado-Lourenco, Leonel, additional, Levin, Michael G., additional, Thacker, Seth, additional, Sethupathy, Praveen, additional, Barter, Philip J., additional, Remaley, Alan T., additional, and Rye, Kerry-Anne, additional

Published
2014
Full Text
View/download PDF

45. RETRACTED: Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial

Author

Huijgen, Roeland, primary, Boekholdt, S. Matthijs, additional, Arsenault, Benoit J., additional, Bao, Weihang, additional, Davaine, Jean-Michel, additional, Tabet, Fatiha, additional, Petrides, Francine, additional, Rye, Kerry-Anne, additional, DeMicco, David A., additional, Barter, Philip J., additional, Kastelein, John J.P., additional, and Lambert, Gilles, additional

Published
2012
Full Text
View/download PDF

47. Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I

Author

Nobécourt, Estelle, primary, Tabet, Fatiha, additional, Lambert, Gilles, additional, Puranik, Rajesh, additional, Bao, Shisan, additional, Yan, Ling, additional, Davies, Michael J., additional, Brown, Bronwyn E., additional, Jenkins, Alicia J., additional, Dusting, Gregory J., additional, Bonnet, David J., additional, Curtiss, Linda K., additional, Barter, Philip J., additional, and Rye, Kerry-Anne, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results